Scarica l'app Stockscreener
28.71
1.17%
-0.34
Dopo l'orario di chiusura:
28.71
Precedente Chiudi:
$29.05
Aprire:
$28.28
Volume 24 ore:
780.29K
Relative Volume:
1.13
Capitalizzazione di mercato:
$1.43B
Reddito:
$2.50M
Utile/perdita netta:
$-131.12M
Rapporto P/E:
-10.10
EPS:
-2.8431
Flusso di cassa netto:
$-112.73M
1 W Prestazione:
-9.46%
1M Prestazione:
-37.05%
6M Prestazione:
+8.34%
1 anno Prestazione:
+176.86%
Intervallo 1D:
$28.00
$29.84
Intervallo di 1 settimana:
$28.00
$32.27
Portata 52W:
$6.71
$53.65
Maze Therapeutics Inc Stock (MAZE) Company Profile
Nome
Maze Therapeutics Inc
Settore
Industria
Telefono
(650) 850-5070
Indirizzo
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
28.71 | 1.43B | 2.50M | -131.12M | -112.73M | -2.8431 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Iniziato | Truist | Buy |
| 2026-03-10 | Iniziato | Mizuho | Outperform |
| 2025-12-04 | Iniziato | Wells Fargo | Overweight |
| 2025-11-14 | Iniziato | Raymond James | Outperform |
| 2025-09-02 | Iniziato | BTIG Research | Buy |
| 2025-07-23 | Iniziato | H.C. Wainwright | Buy |
| 2025-07-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Maze Therapeutics Inc Borsa (MAZE) Ultime notizie
Does Maze Therapeutics Inc have declining or rising EPS2026 Sector Moves & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. - Yahoo Finance
Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors. - The Motley Fool
Harold Bernstein Sells 15,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - MarketBeat
Insider Selling: Maze Therapeutics (NASDAQ:MAZE) SVP Sells 2,500 Shares of Stock - MarketBeat
Maze Therapeutics (MAZE) executive exercises options and sells 15,000 shares - Stock Titan
Maze Therapeutics (MAZE) SVP sells 2,500 shares after option exercise - Stock Titan
Washington University Purchases 70,121 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Maze Therapeutics shares surge after positive Phase 2 data for MZE829 - MSN
Atul Dandekar, CSBO of Maze Therapeutics, sells $220k in Maze stock - Investing.com
Maze Therapeutics (MAZE) CSBO exercises options and sells 7,500 shares - Stock Titan
Paradigm group holds 6.1% of Maze Therapeutics (NASDAQ: MAZE) in Schedule 13G - Stock Titan
Director at Maze (NASDAQ: MAZE) receives 33,417 stock options grant - Stock Titan
Maze Therapeutics (MAZE) director Neil Kumar submits initial Form 3 - Stock Titan
JPMorgan Chase & Co. Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $58.00 - marketbeat.com
Maze Therapeutics, Inc. (MAZE) Gets a Buy from LifeSci Capital - The Globe and Mail
MAZE SEC FilingsMaze Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Maze Therapeutics (MAZE) price target increased by 19.51% to 61.71 - MSN
Maze Therapeutics (NASDAQ:MAZE) Upgraded by Wall Street Zen to Hold Rating - marketbeat.com
Support Test: Is Maze Therapeutics Inc forming bullish engulfing patterns2026 Highlights & Verified Momentum Watchlists - baoquankhu1.vn
Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop (NASDAQ:MAZE) - Seeking Alpha
After a 30.8% Drop Over the Past Four Weeks, Here’s What Could Cause Maze Therapeutics, Inc. (MAZE) to Rebound - Bitget
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE) - Yahoo Finance
Q1 EPS Forecast for Maze Therapeutics Raised by Analyst - MarketBeat
Analysts Offer Insights on Healthcare Companies: Beam Therapeutics (BEAM), Maze Therapeutics, Inc. (MAZE) and Daiichi Sankyo Company (OtherDSKYF) - The Globe and Mail
What date does Maze Therapeutics, Inc.'s (MAZE) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Dow Surges Over 300 Points; Chewy Shares Jump On Upbeat Earnings - Sahm
Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829 - Sahm
Encouraging HORIZON Phase 2 Data and Favorable Safety Support Buy Rating on Maze’s APOL1 Inhibitor MZE829 - TipRanks
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 5.5% Following Earnings Beat - marketbeat.com
MAZE Shareholders Are Encouraged to Reach Out to Johnson - GlobeNewswire
Maze Therapeutics (NASDAQ:MAZE) Given New $110.00 Price Target at HC Wainwright - Defense World
Maze Therapeutics 2025 Annual Report: Pipeline, Strategy, and Clinical Program Overview - Minichart
Decoding Maze Therapeutics Inc (MAZE): A Strategic SWOT Insight - GuruFocus
Maze Therapeutics Executive Sells All Shares Ahead of Q4 Earnings Report - Intellectia AI
MAZE Stock Rating Reiterated by BTIG with $46 Price Target | MAZ - GuruFocus
Top 1% Biotech Crashes Despite 'Overwhelmingly Positive' Data - Investor's Business Daily
Maze Therapeutics reports Q4 EPS (65c), consensus (78c) - TipRanks
Maze Therapeutics Shares Phase II HORIZON Data: MZE829 Cuts Proteinuria in APOL1 Kidney Disease - marketbeat.com
Maze Therapeutics stock rating held at Buy by TD Cowen on trial data - Investing.com UK
Maze Therapeutics stock rating held at Buy by TD Cowen on trial data By Investing.com - Investing.com Australia
Maze Therapeutics share sell-off an ‘overreaction,’ says Raymond James - TipRanks
Maze Therapeutics' (MAZE) "Buy" Rating Reiterated at BTIG Research - marketbeat.com
BTIG reiterates Maze Therapeutics stock rating on trial results By Investing.com - Investing.com Canada
BTIG reiterates Maze Therapeutics stock rating on trial results - Investing.com
Maze Therapeutics falls despite positive mid-stage trial data for lead asset - MSN
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Maze Therapeutics (NASDAQ:MAZE) Shares Gap DownTime to Sell? - MarketBeat
Mizuho reiterates Maze Therapeutics stock rating on phase 2 data By Investing.com - Investing.com Australia
Maze Therapeutics stock rating reiterated at Strong Buy by Raymond James - Investing.com
Truist reiterates Buy on Maze Therapeutics stock after trial data By Investing.com - Investing.com Canada
Maze Therapeutics Inc Azioni (MAZE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Maze Therapeutics Inc Azioni (MAZE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Bernstein Harold | President, R&D & CMO |
Apr 01 '26 |
Sale |
29.46 |
15,000 |
441,904 |
0 |
| Bachrodt Amy | SVP, Finance |
Apr 01 '26 |
Option Exercise |
10.42 |
2,500 |
26,050 |
15,465 |
| Bachrodt Amy | SVP, Finance |
Apr 01 '26 |
Sale |
29.44 |
2,500 |
73,611 |
12,965 |
| Dandekar Atul | CSBO |
Mar 30 '26 |
Option Exercise |
10.42 |
7,500 |
78,150 |
18,003 |
| Dandekar Atul | CSBO |
Mar 30 '26 |
Sale |
29.34 |
7,500 |
220,019 |
10,503 |
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):